XPENG Launches G9 SUV and P7 Sedan for Europe
3.2.2023 10:00:00 EET | Business Wire | Press release
XPENG (NYSE: XPEV and HKEX: 9868), today launched its two latest smart EV models for European markets: G9 flagship SUV, and the new P7 sports sedan. Both models, on show at eCar Expo in Stockholm Feb 3-5, are now available for order in Denmark, Norway, the Netherlands, and Sweden.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005580/en/
Premium electric smart sedan with sports car DNA (Photo: Business Wire)
“XPENG G9 and P7 bring a combination of superior styling, quality, performance and comfort, exemplifying our market-leading technology and innovation. Today also represents a significant milestone as we build our presence in Europe. We believe both vehicles deliver a new level of sophistication and a people-first mobility experience, and will be the electric vehicles of choice for many European customers,” said Brian Gu, Vice Chair and President of XPENG.
G9 features XPENG’s latest powertrain system, battery technology, and advanced driver assistance system (ADAS), fully complemented by a luxurious and immersive cabin experience. The new P7 - an upgraded version of P7 - combines its signature sports sedan profile with greater range, faster charging and a brand new smart cabin.
Faster Charging. Longer Range
XPENG’s new models bring some of the most powerful and advanced EV technology to Europe. XPENG G9 features a new powertrain system with 800 V Silicon Carbide (SiC) platform for ultra-fast charging of up to 300 kW, allowing drivers to add up to 100 km of range in just five minutes. This makes it possible to charge the 98 kWh battery from 10 % to 80% in just 20 minutes. G9 can travel up to 570 km WLTP on a single charge (RWD Long Range), exceptional for the battery size. G9 can be fitted with an electric tow bar, for up to 1,500 kg towed load, to suit European lifestyles.
The new P7 has been optimized with the maximum charging power of up to 175 kW, delivering fast charging from 10% to 80% in only 29 minutes. P7’s range has been improved, offering up to 576 km WLTP on a single charge (RWD Long Range). An electric tailgate and soft-closing doors are introduced for even greater comfort and convenience, along with a heat pump and heated steering wheel for more relaxing winter driving in the colder regions of Europe.
XPENG G9 and P7 are both engineered to meet E-NCAP five-star safety standards and stringent EU WVTA vehicle certification.
Superior Performance. Elegant Design
XPENG G9 and P7 boast superior performance with their advanced systems and elegant aerodynamic profiles, and are available in all-wheel-drive or rear-wheel drive configurations.
G9’s all-wheel drive version boasts up to 551 hp with a maximum torque of 717 Nm, powering acceleration from 0–100 km/h in just 3.9 seconds. The dual-chamber air spring system provides a wide range of stiffness adjustments to help the vehicle handle complex road conditions and ensure optimal ride comfort.
For the new P7, the all-wheel drive version accelerates from 0 to 100 km/h in just 4.1 seconds – outperforming even some sports car models. Brembo brakes also come as standard, giving drivers an extra level of control. All of this comes wrapped up in an exterior using XPENG's "Dynamic Aesthetics" design language that creates a more dynamic sports silhouette.
The new P7 is offered in a stunning range of colour styles, as well as an exclusive Wing Edition featuring scissors doors.
Both models adopt hidden door handles, with extremely low drag coefficients (0.236 for P7 and 0.272 for G9), for lower power consumption and extended range.
Comfort and Intelligence
The cabins of both vehicles use wraparound designs with high-quality finishing and materials to create a warm and comfortable environment. The ergonomically designed front seats feature heating and ventilation functions. To create an even more immersive cabin, both P7 and G9 can be configured with a Dynaudio sound system, producing up to 860 W and 2150 W respectively.
Both XPENG G9 and P7 come equipped with XPENG's proprietary Advanced Driver Assistance System, XPILOT, offering safety, driving, and parking support through a variety of smart functions. These functions are supported by 29 sensors including high-definition millimeter-wave radars, ultrasonic sensors, surround view and high perception cameras, enabling the vehicles to safely tackle multiple driving scenarios.
The upgraded in-car Xmart OS boasts a new 3D UI that supports English, Nederlands, Dansk, Norsk, and Svenska, depending on the market. Xmart OS also comes with the improved "Hey, XPENG" voice assistant, which can distinguish complex voice commands from all four zones of the cabin. These services are supported by wide infotainment screens and a library of in-car apps to assist, inform and entertain drivers and passengers.
G9 and P7 will also support easy and seamless over-the-air (OTA) updates that allow both software and firmware to be improved during normal use.
Expanding Service and Charging Networks
Delivery of the new models will capitalize on the opening of XPENG’s new Delivery and Service Centers in the key markets: at Lørenskog in Norway (opening February 2023), Badhoevedorp in the Netherlands, Stäket, Järfälla in Sweden and Hillerød in Denmark – all opening in the Q2 2023.
XPENG will also open additional authorized service locations with dedicated partners in key European countries by the end of 2023.
XPENG customers can access over 400,000 public charging stations in Europe, by collaboration with major European third-party charging operators and mobility service providers (Plugsurfing and Shell Recharge). With its new models, XPENG will provide third party home charger and installation services together with local partners, to offer customers a seamless easy charging experience.
Warranty
As a brand committed to product quality and offering better customer experiences, XPENG is proud to offer a five-year/120,000 km warranty* as standard for hassle-free ownership. For customers** ordering our new P7 sedan or G9 SUV between February 3 and December 31, 2023, the standard warranty will be extended to seven years/160,000 km from the date of delivery. This extended warranty is linked to the vehicle and is transferable when or if the vehicle is sold.
*For more information on the limited warranty policy, please refer to the warranty booklet.
**For more information on who is eligible for this extended warranty offer, please refer to the warranty booklet.
Pricing, Test Drive and Delivery
Expected starting prices* for the European version G9 are as follows
|
Model: |
XPENG G9 |
||
|
Version |
RWD Standard
|
RWD Long
|
AWD
|
|
Price(MSRP) - Norway (NOK) |
499 900 |
569 900 |
639 900 |
|
Price(MSRP) - Sweden (SEK) |
699 900 |
749 900 |
829 900 |
|
Price(MSRP) - Netherlands (EURO) |
57 990 |
61 990 |
71 990 |
|
Price(MSRP) - Denmark (DKK) |
479 900 |
549 900 |
599 900 |
Expected starting prices* for the new European version P7 are as follows
|
Model: |
XPENG P7 |
||
|
Version |
RWD Long Range |
AWD Performance |
Wing Edition |
|
Price(MSRP) - Norway (NOK) |
439 900 |
479 900 |
649 900 |
|
Price(MSRP) - Sweden (SEK) |
599 900 |
669 900 |
799 900 |
|
Price(MSRP) - Netherlands (EURO) |
49 990 |
59 990 |
69 990 |
|
Price(MSRP) - Denmark (DKK) |
399 900 |
479 900 |
599 900 |
*All prices include VAT and exclude local taxes, registration fees, and delivery costs. Please contact local XPENG representatives for details.
Deliveries for the new P7 will begin in June and G9 deliveries are expected to commence in September.
Customers can contact XPENG’s experience stores (Oslo, The Hague, Stockholm, Copenhagen) for test drive schedules. For more information about the G9 and P7, please visit the dedicated local XPENG websites:
https://heyxpeng.com/no/p7
https://heyxpeng.com/se/p7
https://heyxpeng.com/dk/p7
https://heyxpeng.com/nl/p7
https://heyxpeng.com/no/g9
https://heyxpeng.com/se/g9
https://heyxpeng.com/dk/g9
https://heyxpeng.com/nl/g9
Presskit (visual assets and specs) link
Follow us:
XPENG Twitter
XPENG LinkedIn
XPENG Facebook
XPENG Instagram
XPENG TikTok
XPENG YouTube
About XPeng Inc.
XPeng is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPeng is headquartered in Guangzhou, China. In 2021, the Company established its European headquarters in Amsterdam, along with other dedicated offices in Copenhagen, Munich, Oslo, and Stockholm. The Company’s Smart EVs are mainly manufactured at its plant in Zhaoqing, Guangdong province. For more information, please visit https://heyxpeng.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005580/en/
Contact information
For Media Enquiries:
Email: pr@xiaopeng.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
